Extracted from this filing and checked against the source text.
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.95
Autolus Therapeutics plc announced a restructuring with charges of total restructuring charges of approximately $8 million, consisting primarily of employee severance and related costs affecting all areas of the business (approximately 13% of the Company’s workforce).
- Type
- restructuring
- Charge
- total restructuring charges of approximately $8 million, consisting primarily of employee severance and related costs
- Affected area
- all areas of the business
- Headcount
- approximately 13% of the Company’s workforce
Exact text from the filing
Item 2.05 Costs Associated with Exit or Disposal Activities. On April 29, 2026, Autolus Therapeutics plc (the “Company”) announced its Board of Directors approved a plan to improve operational efficiency and reduce operating expenses. This plan will implement a reduction in force whereby the Company will eliminate approximately 13% of the Company’s workforce, inclusive of employee-related actions that began in the second half of 2025. The Company anticipates that it will complete the implementation of the plan by the third quarter of 2026. Affected employees will be offered separation benefits, including severance payments and, where applicable, temporary healthcare coverage assistance. The Company estimates that it will incur total expenses relating to the realignment of approximately $8 million, consisting of severance and termination-related costs. The Company expects to record a significant portion of these charges in the first half of 2026.
View on SEC.gov